Millennium Management’s Plus Therapeutics PSTV Stock Holding History

Millennium Management’s Portfolio PSTV Stock Details PSTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.2K	Buy	+10,864	New	+$82.4K	﹤0.01%	5449
2025 Q3	–	Sell	-969	Closed	-$8.43K	–	6376
2025 Q2	$8.43K	Buy	+969	New	+$12.7K	﹤0.01%	5724
2023 Q4	–	Sell	-790	Closed	-$26.5K	–	6447
2023 Q3	$26.5K	Buy	+790	New	+$42.4K	﹤0.01%	5597
2023 Q2	–	Sell	-186	Closed	-$20K	–	6574
2023 Q1	$20K	Sell	186 -179	-49%	-$24.1K	﹤0.01%	5865
2022 Q4	$43K	Buy	365 +332	+1,006%	+$52.9K	﹤0.01%	5827
2022 Q3	$6K	Sell	33 -24	-42%	-$5.36K	﹤0.01%	6770
2022 Q2	$12K	Buy	+57	New	+$14.2K	﹤0.01%	6620
2016 Q1	–	Hold	0	–	-$24K	–	3583
2015 Q4	–	Hold	0	–	–	–	3338
2015 Q3	–	Hold	0	–	–	–	3093
2015 Q2	–	Hold	0	–	–	–	2768
2014 Q1	–	Hold	0	–	-$140K	–	3809
2013 Q4	–	Hold	0	–	–	–	3306

Other funds holding PSTV

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management's PSTV Position: Q1 2026 in Review

Millennium Management opened a new position in Plus Therapeutics (PSTV) in Q1 2026: 10,864 shares worth $44.2K. The stake represents ﹤0.01% of the portfolio and ranks #5449 among its holdings. This is a return to the name: Millennium Management previously reported a position in PSTV as recently as Q2 2025.

Millennium Management first reported a position in PSTV in Q2 2022 and has held it in 7 quarters since. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

Millennium Management held 10,864 shares of Plus Therapeutics worth $44.2K as of Q1 2026.
Plus Therapeutics was a new Millennium Management position in Q1 2026.
Plus Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #5449 holding.
Millennium Management first reported a position in Plus Therapeutics in Q2 2022 and has held it in 7 quarters since.
23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.